Pharmamarketeer
onderzoek

AbbVie presents positive results from phase 3 MURANO trial of venetoclax in combo with rituximab to treat CLL at ASH meeting

9 december 2019
Pharma Biz

Phase 3

AbbVie, a research─based global biopharmaceutical company, presented long─term data from a post─hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with Venclexta/Venclyxto.

 

Voor andere berichten over phase III berichten, KLIK HIER! 

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)